This revision of the British Association for Psychopharmacology (BAP) guidelines for treating depressive disorders with antidepressants (Montgomery et al., 1993a) was undertaken in order to update the guidelines and to make the recommendations explicitly evidence based (Shekelle et al., 1999) .
not result in a format that is sufficiently brief and easy to use in everyday practice, especially for general practitioners. Therefore these guidelines are intended as a resource to inform everyday practical guidelines.
Depressive disorders: diagnosis and detection

Nature and diagnosis of depressive disorders
Depressive states cover a spectrum between normal sadness at one end and severe illness at the other. The definition and diagnosis of different types of depressive disorders may cause confusion. The majority of depressive states are at the mild to moderate end of the spectrum and it is these that predominate primary care (Blacker and Clare, 1988; Salokangas et al., 1996; Schwenk et al., 1996) . The historical distinction between major depression 'reactive' to external stressors and that occurring autonomously or 'endogenously' has not been found generally useful because life events commonly precede all types of major depression irrespective of clinical picture; the possible exception is a minority of patients with recurrent melancholic/psychotic major depression (Paykel, 1978; Brown et al., 1994) . There is also no clear relationship between apparent 'cause' of depression and response to antidepressant drug treatment for non-hospitalized patients, although some suggestion that hospitalized patients with an 'endogenous' compared with 'non-endogenous' picture respond better to antidepressants and to electroconvulsive therapy (ECT) (Rush and Weissenburger, 1994) . Patients with major depression can be divided into various subgroups. In general, the evidence that this affects treatment choice is not strong enough to warrant separate consideration in these guidelines (Fava et al., 1997 ). An exception may be a subgroup of depressed patients with 'atypical' depression. We have excluded major depression in bipolar patients and patients with psychotic symptoms for whom psychiatric referral is indicated. There are specific treatment implications involving additional treatment with mood stabilizers in the first case (Frances et al., 1998) and antipsychotic drugs and/or electroconvulsive ECT treatment in the second case (Chan et al., 1987; Depression Guideline Panel, 1993a) .
Identification of the presentation of depressive disorder guides treatment (Ia-Ib)
Standardized criteria allow for greater reliability of diagnosis but there are minor differences between the two major classification systems, the 4th Revision of the American Psychiatric Association's Diagnostic and Statistics Manual (DSM-IV) and the 10th Revision of the International Classification of Diseases (ICD-10) (Andrews et al., 1999) . To avoid confusion, we have used DSM-IV criteria as the basis for these guidelines. It is possible to distinguish three presentations of patients that relate to response to treatment. Table 2 describes their correspondence to DSM-IV and ICD-10. The first is major depression. This is a condition with sufficient symptoms to meet a syndromal diagnosis, the criteria for which include at least 2 weeks of five or more symptoms, one of which must be depressed mood or loss of interest or pleasure 4 JOURNAL OF PSYCHOPHARMACOLOGY 14(1) 
Categories of evidence for causal relationships and treatment
Ia Evidence from meta-analysis of randomized controlled trials Ib Evidence from at least one randomized controlled trial IIa Evidence from at least one controlled study without randomization IIb Evidence from at least one other type of quasi-experimental study III Evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-control studies IV Evidence from expert committee reports or opinions and/or clinical experience of respected authorities
Strength of recommendation
A Directly based on category I evidence B Directly based on category II evidence or extrapolated b recommendation from category I evidence C Directly based on category III evidence or extrapolated b recommendation from category I or II evidence D Directly based on category IV evidence or extrapolated b recommendation from category I, II or III evidence a Shekelle et al., 1999. b Extrapolation may be necessary because the evidence may be only indirectly related, cover only a part or the area of practice under consideration or be contradictory. Adjustment disorder with depressed mood/mixed anxiety Adjustment disorder: depressive reaction/mixed anxiety and depressed mood (309) and depressive reaction (F43.2) Other mood (affective) disorders (F38) Dysthymia Dysthymia (300.4) Dysthymia (F34.1) ( Table 3 ). The number of symptoms, the severity of individual symptoms and resulting disability are each important in deciding on the severity of the major depression. Patients with 'mild' major depression will usually just have a sufficient number of relatively mild symptoms to meet the diagnosis and have minimal objective disability. Just below this threshold is the second presentation consisting of patients with recent-onset milder depressions (i.e. not meeting full syndromal diagnosis for major depression), often associated with significant anxiety symptoms. Patients with psychological responses to life stresses (e.g. bereavement and adjustment disorders) will often come into this category. The third presentation consists of patients with dysthymia, a chronic depressive state (defined as greater than 2 years duration) which does not meet full criteria for major depression and is not the consequence of a partly resolved major depression. The nature of the depressive picture frequently varies over time within individuals (Judd et al., 1998) so that a patient may present at different times with any of these pictures. Patients with dysthymia are likely to experience episodes of major depression ('double depression') and these patients, together with those with recurrent major depression, are more likely to have incomplete recovery and chronic symptoms (Keller, 1994; Angst, 1997; Judd et al., 1998) .
The size and nature of the problem National surveys reveal that major depression is common in nearly all countries but reported rates differ substantially, partly due to variations in methodology and also real differences in prevalence that are attributable to social factors (Weissman et al., 1996) . Annual prevalence in Western countries is reported as between 3% and 10% with a weekly prevalence in the UK of 2.3% (Jenkins et al., 1997) . Milder depressive states are more common with a UK weekly prevalence of 7.7% (Jenkins et al., 1997) . The prevalence is approximately 2-3 times higher in women than men (Weissman et al., 1996) although this sex difference disappeared above 55 years of age in one survey (Bebbington et al., 1998) . Dysthymia has been reported to have an annual prevalence rate of 2.5% (Kessler et al., 1994) .
Approximately 80% of people who have received psychiatric care for an episode of major depression will have at least one more episode in their lifetime and a median of four episodes in a lifetime. The median duration of an episode is approximately 20 weeks. Recovery from prolonged episodes continues to occur over time but approximately 12% of patients have a chronic unremitting course (Judd, 1997) . The outcome of neurotic disorders seen in primary care, which include a large proportion of depressive disorders, also appears poor with only approximately one-third remaining well over 11 years and 18% having a chronic course (Lloyd et al., 1996) . A meta-analysis of 12 studies of elderly community patients with major depression showed a poor outcome after 2 years; 20% of patients had died and almost half of those remaining alive were still depressed (Cole et al., 1999) .
In 1990, major depression was estimated as the fourth leading specific cause of disability on a global scale and second only to ischaemic heart disease in developed countries (Murray and Lopez, 1997) .
These epidemiological findings translate into presentation in general practice where 5-10% of consecutive patients have major depression with a similar number having milder depressive states (Freeling et al., 1985; Barrett et al., 1988; Blacker and Clare, 1988; Tiemens et al., 1999) .
Depressive states frequently co-exist with physical illness (Wells et al., 1988) and other psychiatric disorders, notably alcohol and drug misuse, anxiety and obsessive-compulsive disorders and eating disorders in women (Weissman et al., 1996) .
Detection
Thirty to 50 percent of cases of depression in primary care and medical settings are not detected (Freeling et al., 1985; Ronalds et al., 1997; Rost et al., 1998) and have less severe disorders and function better than detected patients (Schwenk et al., 1996; Ronalds et al., 1997; Simon et al., 1999a Recurrent thoughts of death (not just fear of dying), or suicidal ideation, or a suicide attempt, or a specific plan for committing suicide.
B The symptoms cause clinically significant distress or impairment in functioning.
C The symptoms are not due to a physical/organic factor or illness The symptoms are not better explained by bereavement (although this can be complicated by major depression).
Recommendations: Diagnosis
Identification of the following three presentations of patients with depressive symptoms guides treatment choice (A) ( Table 2) : q major depression (major depressive episode according to DSM-IV criteria, Table 3 ). q milder depression (recent onset depressive symptoms not meeting DSM-IV criteria for depressive episode). q dysthymia, a chronic milder depressive disorder (at least 2 years of depressive symptoms not meeting DSM-IV criteria for depressive episode) which is not a consequence of a partly resolved major depression.
Subdivision of major depression into mild, moderate and severe, guides treatment choice (B) although precise definitions are difficult in practice. q severe major depression is characterized by the presence of all, or nearly all, DSM-IV depressive symptoms to a clinically severe degree and marked functional impairment in all areas of life. q mild through to moderate severity ranges from a threshold number of symptoms with minimal functional impairment through to marked symptoms and impairment of function.
patients with major depression remain depressed 1 year later (Judd, 1997; Rost et al., 1998) with little difference reported between detected and undetected patients (Rost et al., 1998; Simon et al., 1999a) . Depressive disorders are missed for a number of reasons (Tylee et al., 1995; Priest et al., 1996; Davidson and Meltzer-Brody, 1999) . On the patients' side, these include stigma, non-recognition and/or beliefs about the condition or its treatment. The doctor may lack the skills or time to detect depression, be misled by physical complaints, perceive the symptoms as an understandable reaction, or avoid the diagnosis through lack of skills, time or belief in treatment. Improving detection is a necessary first step for providing appropriate treatment. There is some evidence that strategies to increase the awareness and knowledge of both the public and doctors about depressive disorders and to train doctors in the detection and treatment of depressive disorders are effective (Grimshaw and Russell, 1993; Stevens et al., 1997; Paykel et al., 1998) .
Detection of depressive disorders has been associated with improved short, but not medium to longer-term outcome compared with non-detection (IIb)
Detection alone has not been found to be associated with improved medium to longer-term outcome (Dowrick and Buchan, 1995; Tiemens et al., 1996; Ronalds et al., 1997; Rost et al., 1998; Simon et al., 1999a) , although it may be associated with modestly greater short-term improvement (Simon et al., 1999a) .
Restructured services are required to improve mediumterm outcome but long-term benefit has not been demonstrated (Ib)
The evidence that educational programs for doctors improve treatment or outcome is inconsistent (Rutz et al., 1992; Lin et al., 1997) and restructuring of services appears to be needed to achieve better medium-term outcomes involving increased patient education, intensity of treatment and monitoring and encouraging patient compliance with medication (Katon et al., , 1996 . It has yet to be demonstrated that longer-term outcome is improved and a 19 month follow-up of the Katon et al. (1995 Katon et al. ( , 1996 studies failed to show persisting benefit . Recent trends show that antidepressant prescribing by primary care physicians is increasing (Olfson and Klerman, 1993; Mason et al., 1999) but the impact of this on the outcome of depressive disorders is unknown.
Screening questions and self-report scales for the detection of depressive disorders are generally fairly sensitive but not very specific (i.e. have relatively few false negatives but many false positives) (Wilkinson and Barczak, 1988; Depression Guideline Panel, 1993b; Whooley et al., 1997) . Some of these methods are described in Table 4 . The lack of specificity and the requirement to ask about further depressive symptoms (Table 2) means that they are most useful when a depressive disorder is suspected and also in high-risk populations.
Psychiatric/specialist referral
Certain conditions such as high suicide risk, psychotic major depression and major depression in bipolar patients have specific treatment implications (Chan et al., 1987; Depression Guideline Panel, 1993a; Frances et al., 1998) which are generally regarded as requiring specialist expertise. There are no controlled data related to indications for referral. Goldberg et al., 1988. c Zigmond and Snaith, 1983. d Wilkinson and Barczak, 1988. Recommendations: Detection Improving the outcome of major depression requires a multifaceted approach (B) including: q education of public and doctors about the detection and treatment. q adoption of clinical guidelines for treatment. q restructuring service provision to ensure that guidelines are applied. Use of screening questions or questionnaires (Table 4 ) may be helpful in high-risk groups because these have high sensitivity, but poor selectivity limits their routine usefulness (C).
Recommendations: Psychiatric referral
Referral to psychiatric services is indicated if there is a : q risk of suicide (D). q psychotic symptoms (D). q a history of bipolar affective disorder (D).
Consultation with, or referral to, a psychiatrist (or a specialist in the treatment of affective disorders), is appropriate: q when the practitioner feels insufficiently experienced to manage a patient's condition (D). q if two or more attempts to treat the patient's depressive disorder have failed or resulted in only partial response (D). (Depression Guideline Panel, 1993b; Schulberg et al., 1998 Schulberg et al., , 1999 meaning that three to four patients need to be treated with an antidepressant for one more patient to respond than on placebo (this is known as the number needed to treat; NNT). In a naturalistic study without a placebo arm, recovery rates in moderately depressed patients randomized to treatment as usual were much lower at 8 months (only 20%) than those randomized to psychotherapy or antidepressant drug treatment (approximately 50%) (Schulberg et al., 1996) . A systematic review of antidepressant treatment in depressive disorder associated with physical illness has shown similar response rates (Gill and Hatcher, 1999) .
Acute treatment
Response to antidepressants in major depression is unrelated to prior life events (Ib), however, response to placebo appears higher with prior life events (IIb) and in primary care settings (Ib)
Response to antidepressants is unaffected by whether or not the major depression was preceded by a life event (Vallejo et al., 1991; Tomaszewska et al., 1996; Ezquiaga et al., 1998) , although response to placebo may be greater if there has been a precipitating life event (Brown et al., 1992) . A naturalistic controlled primary care study found a high placebo response rate with a 47% remission rate on placebo at 6 months compared with 54-61% on antidepressants (Malt et al., 1999) .
Antidepressants do not appear more effective than placebo in acute milder depressions or very mild major depression (Ib)
An RCT with post-hoc analysis of patients with acute milder depressions showed no advantage of amitriptyline over placebo (Paykel et al., 1988) where a good response was seen to both drug and placebo. A similar finding occurred in a structured depression treatment programme which enhanced medication compliance over usual treatment (Katon et al., 1996) . In contrast, both studies did show an effect in improving outcome in patients with major depression. Differences in outcome between antidepressant drug-treated and untreated major depression are difficult to demonstrate in naturalistic studies (Brugha et al., 1992; Ronalds et al., 1997) . One proposed reason is that treatment is often inadequate with only approximately 25-50% of patients with detected major depression receiving the recommended intensity of antidepressant drug treatment in both primary care and psychiatric settings (Glick et al., 1991; Rost et al., 1998; Davidson and Meltzer-Brody, 1999) . However, in primary care, a greater adequacy of treatment has not been shown to significantly improve clinical outcome Revicki et al., 1998) whereas there is some evidence that outcome may also improve in more severely ill patients in psychiatric care (Goethe et al., 1988; Glick et al., 1991; Ramana et al., 1999) . A likely reason is that up to a half of patients in primary care have mild major depression where the efficacy of antidepressant treatment is unproven (Salokangas et al., 1996; Schwenk et al., 1996) . HDRS scores in these patients are generally between 12 and 16 (Schwenk et al., 1996; Ronalds et al., 1997) whereas nearly all controlled trials have been in at least moderately severe major depression with HDRS scores above 17. Paykel et al. (1988) found that patients with HDRS scores of 13 or greater benefited from amitriptyline compared with placebo treatment but, in those with scores below 13, who were a mixed group of milder depressions and mild major depression, response was equally good to both treatments. Ottevanger (1991) found an even higher threshold of HDRS score (17-18) before antidepressant treatment showed benefit over placebo. Evidence is therefore lacking that patients with very mild major depression benefit from antidepressant treatment. Antidepressants appear to have increasing benefit over placebo as the severity of depression increases, with the greatest separation being observed in more severe cases (Ottevanger, 1991; Angst et al., 1993) .
Antidepressants are effective in the acute treatment of dysthymia (Ia)
A meta-analysis of 15 RCTs in dysthymia showed that 55% of patients responded on antidepressant drug treatment compared with 30% on placebo (NNT = 4) (Lima and Moncrieff, 1999) .
The degree and number of depressive symptoms varies with time in patients who have previously had a major depression (Judd et al., 1998) . The benefits of treatment in milder depression occurring in this context are not known.
Choice of antidepressant drug versus alternative treatment Specific psychological treatment is effective in the treatment of major depression with greatest evidence
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Recommendations: Indications for antidepressants Major depression: antidepressants are a first line treatment irrespective of environmental factors (A). At the mildest severity the benefit is uncertain.
Dysthymia: antidepressants are a first line treatment (A).
Acute milder depressions at initial presentation: q antidepressants are not indicated (B). q education, support and simple problem solving are recommended (D). q monitor for persistence or for the development of major depression (D).
Persistent milder depression: a trial of antidepressants is recommended (D).
Milder depression with history of major depression: consider treatment with antidepressants (D).
for mild to moderate severity (Ia-Ib). The efficacy of non-directive counselling is uncertain (Ib)
Controlled trials have shown several specific psychological treatments to be effective for major depression including cognitive behaviour therapy and behaviour therapy (Scott, 1995; Gloaguen et al., 1998) , interpersonal psychotherapy (Weissman and Markowitz, 1994) and problem solving therapy (Mynors-Wallis et al., 1995) .
No psychotherapy emerges as being superior to others although comparisons are limited. Evidence for the efficacy of psychological treatments is stronger for mild to moderate than severe major depression (Persons et al., 1996) .
There have been few studies examining the efficacy of nondirective counselling in major depression as most studies have involved a mixture of milder depressive and anxiety disorders (Boot et al., 1994; Friedli et al., 1997; Harvey et al., 1998) . Some studies do suggest that non-directive counselling may be effective. In postnatal major depression, it was better than treatment as usual (Holden et al., 1989) and patients with higher scores on the Beck Depression Inventory (possibly indicating a greater likelihood of a major depression) did appear to benefit in the Friedli et al. (1997) study by post-hoc analysis. While efficacy cannot be ruled out, the evidence is therefore not as strong as for specific therapies.
Specific psychological treatments, antidepressants, and the combination of the two appear equally effective in mild to moderately severe major depression (Ia). There is uncertainty with regard to relative efficacy in more severely ill patients
No overall difference in efficacy between cognitive behaviour therapy and tricyclic antidepressants was found using individual patient data (i.e. mega-analysis) of a subgroup of outpatients with moderate to severe major depression from four randomized controlled trials but patient numbers were small (DeRubeis et al., 1999) . Thase et al. (1997) in a mega-analysis of six studies found equal efficacy for combined drug-psychotherapy compared with psychotherapy in mild to moderately depressed patients but a poorer response to psychotherapy alone in moderate to severely depressed patients. Again, patient numbers were small and some treatments and combinations were not represented. Evidence is lacking about the efficacy of specific psychotherapies in severely ill hospitalized patients (Persons et al., 1996; Thase and Friedman, 1999) ; in these patients cognitive deficits may be expected to impair ability to engage with psychological treatment (Murphy et al., 1998) .
Controlled evidence for the efficacy of specific psychotherapies in dysthymia is lacking (III)
Open studies have suggested that dysthymia might respond to interpersonal or cognitive behaviour therapy (Markowitz, 1994) but we are not aware of any RCTs.
Non-directive psychotherapy is probably ineffective in milder depression (Ib)
Non-directive psychotherapy has not been shown to improve medium and longer-term outcome in patients with 'emotional difficulties' which are likely to include milder depressions (Friedli et al., 1997; Harvey et al., 1998) although short-term improvement may be more rapid (Boot et al., 1994) . Further studies have been carried out but the results are not available at the time of writing.
There is no controlled evidence available for specific psychotherapies in milder depression.
In poorly defined milder depressive states there is evidence for short-term efficacy of St John's wort (Ia), bibliotherapy (Ia) and exercise (Ia)
Alternative treatments have generally been investigated in poorly defined groups of people with milder depressive disorders. St John's wort (active ingredient believed to be hypericum) was found to be more effective than placebo and equal to antidepressant drugs in a meta-analysis of 27 studies (Linde and Mulrow, 1999) . There are however, uncertainties about dosing, standardization of active ingredients and an absence of longer-term efficacy data. Similar limitations apply to bibliotherapy (based on Cognitive Behaviour Therapy, e.g. Burns, 1983) for which a meta-analysis of six studies found a short-term benefit over control treatment in subjects with depressive symptoms (Cuijpers et al., 1997) , and exercise for which a meta-analysis of 80 trials showed some benefit (Ernst et al., 1998) .
Which antidepressant drug?
Antidepressant drugs have similar efficacy for the majority of patients with major depression (Ia) Systematic reviews and meta-analyses suggest that the commonly available antidepressants have comparable efficacy in the majority of patients seen in primary care or outpatient psychiatric settings (Song et al., 1993; Anderson, 1997 Anderson, , 1999 Geddes et al., 1999) .
Monoamine oxidase inhibitors (MAOIs) may be less effective than tricyclic antidepressants (TCAs) in hospitalized patients but more effective in nonhospitalized patients with 'atypical' depression (Ia)
A systematic review and meta-analysis of MAOIs found evidence 
Recommendations: Alternatives to antidepressants
Major depression: q for mild to moderate severity specific psychological treatments are an effective alternative treatment to antidepressants (A). Choice will depend on availability and patient preference. q in severely ill hospitalized patients use antidepressants in preference to psychological treatments for first line treatment (D).
Dysthymia: use antidepressants in preference to psychological treatments for first line treatment (D).
Milder depression: neither antidepressants nor specific psychological treatment are indicated first line (B).
Combined pharmacological-depression specific psychological treatment is not first line treatment for most patients with major depression (A) but may be considered for more severely ill patients (B).
(5) St John's wort, bibliotherapy and exercise are not first line alternatives to antidepressants for major depression or dysthymia (D). For patients requesting alternative treatment, these are reasonable choices in less severe depressive disorders (B).
that phenelzine and isocarboxazid were less effective than TCAs in hospitalized patients . Conversely, traditional MAOIs were found to be more effective than TCAs (imipramine in nearly all cases) in outpatients with 'atypical' depression, although this was based mainly on an extensive series of studies by one group . 'Atypical' depression is defined by mood reactivity (i.e. mood can improve in response to environmental stimulation) and at least one associated symptom (increased appetite/weight gain, increased sleep, severe fatigue/leaden heaviness of limbs, sensitivity to rejection as a personality trait). It appears likely that the difference is due to relative inefficacy of imipramine in these patients Sotsky and Simmens, 1999) . Studies of selective serotonin reuptake inhibitors (SSRIs) in atypical depression do not allow conclusions to be drawn about their efficacy relative to TCAs or MAOIs (Stratta et al., 1991; Lonnqvist et al., 1994; Pande et al., 1996; Partonen and Lonnqvist, 1996) . Given the dietary restrictions needed when taking MAOIs, together with tolerability and safety problems, they remain a second line treatment in spite of possible increased efficacy in this group of patients. (Anderson, 1998 (Anderson, , 1999 although a meta-analysis with fewer studies and different methodology found the advantage did not reach statistical significance (Geddes et al., 1999) . Venlafaxine was also found to have greater efficacy than SSRIs, more apparent at doses of 150 mg and above (Einarson et al., 1999; Entsuah and Rudolph, 1999; Anderson, unpublished data) . In two meta-analyses, a small advantage to amitriptyline compared with SSRIs was found in one (Anderson, 1999) but not the other (Geddes et al., 1999) .
Newer antidepressants are better tolerated than older TCAs (Ia) and are safer in overdose (III)
Antidepressants differ in their side-effect profile, their potential to interact with other drugs and in safety in overdose. Selected drugs are displayed in Table 5 . In choosing between different drugs, the 'overall' side-effect burden or tolerability determined from systematic reviews may be difficult to interpret given the different side-effect profiles. Meta-analyses of short-term studies have largely focussed on comparisons between SSRIs and older antidepressants. SSRIs do cause significantly lower dropout rates compared with TCAs but the absolute difference is only 3-5% Anderson, 1999) ; however, this difference may increase with length of treatment (Anderson, 1999) and be greater in everyday practice (Martin et al., 1997) and so the clinical importance remains unclear. A meta-analysis of studies involving 'second generation' antidepressants (principally trazodone and mianserin) found comparable tolerability with SSRIs (Hotopf et al., 1997) . The side-effect profiles of different drugs do, however, differ (Table 5 ). Elderly patients have higher discontinuation rates due to side-effects than younger patients in controlled trials, but it has yet to be demonstrated that newer antidepressants are better tolerated in this group (Mittmann et al., 1998; Anderson, 1999) .
SSRIs are more likely than older TCAs to be prescribed at recommended doses for an adequate period (III)
There is consistent evidence from prescription monitoring that older TCAs are commonly prescribed at lower than recommended doses and for a shorter than recommended duration. SSRIs are nearly always prescribed at doses proven to be effective and appear more likely to be prescribed for an adequate duration (Rosholm et al., 1997; Donoghue, 1998; Dunn et al., 1999; Isacsson et al., 1999) . There is, however, no direct evidence that patients prescribed SSRIs have a better outcome than those on TCAs. A recent naturalistic study showed that patients stopped taking TCAs more often than fluoxetine when each was started as the initial treatment. However, they swapped to another drug and were no less likely to continue on an antidepressant than patients started on fluoxetine and there was no difference in clinical outcome at 2 years (Simon et al., 1999b) .
Choice of drug has to be related to the individual patient and detailed consideration of individual situations and individual drugs is outside the scope of these guidelines. Many factors are based on clinical experience and judgement rather than controlled evidence. Potential or unknown risks should be minimized in cases where there is physical illness (e.g. avoiding older TCAs in patients with cardiac disease or those on hypotensive drugs where there might be risk of falls), pregnancy (experience is greater with older drugs) and previous history of overdose (drugs with lower lethality are to be preferred). Some associated psychiatric conditions have specific indications for treatment. Obsessive-compulsive disorder responds preferentially to drugs inhibiting serotonin reuptake (Piccinelli et al., 1995) and there is weaker evidence for a similar benefit in panic disorder (den Boer and Westenberg, 1988) . Major depression associated with these conditions logically may be treated with a serotonin reuptake inhibitor in preference to an antidepressant with another mechanism of action.
Patient preference may be expected to enhance compliance with treatment although controlled data are lacking.
Newer antidepressants are more expensive than older drugs but current pharmacoeconomic data do not favour initial treatment with one antidepressant over another (Ib) Drug acquisition costs are only a small part of the overall costs of treating depressive disorders. There are problems with the design of studies, comparing different health care systems and relating results to clinical practice. A 'real life' randomized study in a US health maintenance organization did not find that initial choice of fluoxetine compared with two TCAs resulted in any difference in overall outcome or cost of treatment over 2 years treatment (Simon et al., 1999b) .
Practical issues in prescribing
Structured interventions involving initial weekly contact are associated with improved treatment compliance and short-term outcome (Ib) Direct evidence for the optimum frequency of monitoring of patients is lacking. Antidepressant drug counselling at weeks 2 and 8, in addition to usual care, improved treatment adherence (Peveler et al., 1999) and naturalistic studies of intervention packages which improved short-term improvement compared with usual care utilized weekly visits for the first 4-6 weeks Schulberg et al., 1996) . The need to monitor response, side-effects, compliance with treatment and suicide risk also suggest that weekly monitoring is advisable in the first phase of treatment. Psychological autopsy shows that 9-33% of depressed patients committing suicide had been receiving antidepressants (Isacsson et al., 1992; Isometsa et al., 1994) . A meta-analysis of 12 short-term studies involving fluoxetine against TCAs and placebo showed that 3% of previously non-suicidal patients developed suicidal ideation during treatment, with no significant difference in the incidence between treatments (Beasley et al., 1991) .
Compliance with taking antidepressants is improved by drug counselling, but not by information leaflets alone (Ib)
Drug counselling, including information about depression, almost trebled the odds of continuing antidepressants at 12 weeks whereas information leaflets alone had no effect (Peveler et al., 1999) , even though patients report that educational materials are helpful (Robinson et al., 1997) . Other structured intervention packages which improved medium-term outcome included patient education and discussion about the importance of medication (Katon et al., , 1996 .
Older TCAs appear to be more effective at a dose of 125-150 mg compared with 75 mg (Ib) and probably lack antidepressant efficacy below 75 mg (IIa). The degree of benefit from adequate treatment appears to increase with severity of depression (II-III)
The issue of adequate dose is of most relevance to TCAs where there is consistent evidence that they are usually prescribed below recommended doses in contrast to SSRIs where dose formulations tend to ensure adequate dosing (Donoghue, 1998; Dunn et al., 1999) . However, the evidence about what comprises an adequate dosage of TCAs is poor. For some TCAs, plasma concentration relates to efficacy (Task Force on the Use of Laboratory Tests in Psychiatry, 1985) and two studies have found a daily dose of 125-150 mg of amitriptyline more effective than 75 mg (Blashki et al., 1971; Paykel et al., 1988) . However, there is great interindividual variation in plasma concentration for all drugs and a difficulty in demonstrating clear-cut dose effects on efficacy in systematic reviews (Anderson, 1999; Bollini et al., 1999) . Recent primary care cohort studies comparing depressed patients treated with 'less than recommended' and 'adequate' antidepressant treatment found no difference in clinical outcome between groups Revicki et al., 1998) although adequately treated patients had a faster improvement rate and lower costs and medical treatment (Revicki et al., 1998) . A drug counselling intervention which improved adherence to treatment was associated with improved outcome in patients with major depression receiving at least 75 mg of amitriptyline or dothiepin daily but not if the dose was below 75 mg (Peveler et al., 1999) . A more consistent improvement in outcome has been described for 'adequately' compared with 'inadequately' treated depressed hospitalized patients (Goethe et al., 1988; Glick et al., 1991; Ramana et al., 1999) .
Lower doses of antidepressants are usually recommended in the elderly (British National Formulary, 1999) in whom higher plasma concentrations for a given dose are generally found (Hammerlein et al., 1998) . Direct evidence that lower doses have acute efficacy in the elderly is, however, lacking. Increases in dosage have typically been between every 3-7 days in studies and clinical practice. If a patient appears to respond to a 'low' dose of an antidepressant, there is no controlled evidence about whether or not to continue dose titration; limited evidence from continuation studies suggests that it is probably best to achieve a dose of proven efficacy, particularly in more severely depressed patients.
Side-effects from antidepressant medication are related to dose (Ia)
The incidence of side-effects increases with dose (Bollini et al., 1999) . Clinical experience suggests that upward titration of TCAs is advisable because of side-effects whereas most new antidepressants can be initiated at doses shown to be therapeutic. It is accepted clinically that many patients become tolerant to sideeffects with continued treatment and there is evidence that this occurs with SSRIs (Tamura et al., 1998; Trivedi et al., 1998) but the anticholinergic side-effects of TCAs appeared no less severe in patients on long-term treatment compared with those who had recently started treatment (Bryant et al., 1987) .
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Recommendations continued
In the absence of special factors, choose antidepressants which are better tolerated, safer in overdose and more likely to be prescribed at effective doses (C). There is most evidence for SSRIs; lofepramine, mirtazapine, nefazodone, reboxetine and venlafaxine are also relatively safe and well-tolerated.
In severely ill hospitalized patients, and in other situations where maximizing efficacy is of overriding importance, consider an older TCA or venlafaxine at a dose of 150 mg or greater in preference to an SSRI (B) or MAOI (B).
Factors to consider in choosing an antidepressant include: q previous treatment response to a particular drug (D). q tolerability and adverse effects of a previously given drug (D). q likely side-effect profile (e.g. sedation, weight gain) (C). q low lethality if history or likelihood of overdose (D). q concurrent physical illness or condition that may make the antidepressant more noxious or less well-tolerated (C). q concurrent medication that may interact with the antidepressant drug (C). q associated psychiatric disorder that may specifically respond to a particular class of antidepressant (e.g. obsessivecompulsive disorder and serotonin reuptake inhibitors) (C). q patient preference (D).
Dysthymia: treat using the same principles as for major depression (D).
Early or non-persistent improvement in depressive symptoms may be due to placebo response (IIb)
Early abrupt improvement (before completion of 2 weeks treatment) is seen in patients on both placebo and antidepressant drug treatment and is less likely to be sustained than gradual improvement or later responses on drug treatment. This suggests that non-persistence of improvement or relapse in the first few weeks of treatment are due to loss of a placebo effect (Quitkin et al., 1984 (Quitkin et al., , 1987 .
Studies of the treatment of dysthymia suggest a similar acute treatment course to that seen in major depression (Lima and Moncrieff, 1999 ) but other evidence is lacking.
Management when initial treatment fails Eventual response is unlikely if no improvement is evident after 4 weeks of treatment (Ib) although elderly patients may take longer to respond (IIb)
Response to antidepressants in major depression is not immediate and traditionally a delay of 2 weeks is described. Improvement within the first few weeks of treatment is associated with more frequent eventual response (Katz et al., 1987; Koran et al., 1995) ; if there has been no improvement by 4 weeks, response is unlikely by continuing with the same treatment although a proportion of those with modest improvement may continue to improve and meet criteria for response at 6 weeks (Quitkin et al., 1984 (Quitkin et al., , 1996 . There is some evidence that the elderly may take longer to respond and patients continued to respond between 6 and 9 weeks in one study (Georgotas et al., 1989) .
If a patient has not responded, it is important to review whether the diagnosis is correct, whether there are concurrent physical or psychiatric conditions, and to check that the initial treatment has been adequately given. Compliance with antidepressant medication is relatively poor ranging from 40% to 90% in different studies with a mean of 65% (Cramer and Rosenheck, 1998) . Inadequate treatment may be associated with poorer outcome as discussed above. Other factors associated with lack of recovery from major depression include longer duration of illness (Bielski and Friedel, 1976; Conti and Dell'Osso, 1989; Sotsky et al., 1991; MynorsWallis and Gath, 1997) ; chronic social difficulties and continuing life events (Lloyd et al., 1981; Vallejo et al., 1991; Ronalds et al., 1997) ; melancholic, psychotic and more severe major depression (Kocsis et al., 1990; Nelson et al., 1990; Duggan et al., 1991; Keller et al., 1992; Rush and Weissenburger, 1994; Fava et al., 1997) ; dysthymia (Sotsky et al., 1991; Gormley et al., 1999) ; and severe personality disorders and neurotic and depressive personality traits (Black et al., 1988; Shea et al., 1990; Sato et al., 1993; Surtees and Wainwright, 1996; Ezquiaga et al., 1998; Gormley et al., 1999) . Comorbidity with other psychiatric disorders has not consistently been associated with poorer outcome, apart from an association with anxiety disorders (Fava et al., 1997; Emmanuel et al., 1998) , although this may be because they are associated with greater severity of major depression (Coryell et al., 1992; Rodney et al., 1997) . Coexisting physical illness is not generally associated with poorer response (Coulehan et al., 1997; Lima and Moncrieff, 1999) .
Strategies with evidence for efficacy following initial non-response to treatment with an antidepressant are increasing the dose (Ib), switching drug (II-III), augmentation with lithium (Ia), augmentation with triiodothyronine (Ia), ECT (IIb-III) and adjunctive psychotherapy (Ib)
The evidence relating drug dose to response has been reviewed above and it is important to make sure that a dose that has been shown to be effective is being taken. Determining plasma drug levels may be helpful for older TCAs where therapeutic plasma drug ranges have been proposed (Task Force on the Use of Laboratory Tests in Psychiatry, 1985) . There is limited evidence for the efficacy of increasing antidepressant dose when faced with non-response. One small randomized study found that increasing the dose of fluoxetine to 60 mg daily in patients who had not responded to 20 mg for 8 weeks was more effective than augmentation with lithium or desipramine (Fava et al., 1994b) .
Increasing the dose appears a logical step, especially as there is wide inter-individual variability in plasma concentration of antidepressants and associated uncertainty about what is an effective dose for an individual patient.
There are no RCTs comparing continuation of the original drug with switching to a different antidepressant. The quality of evidence about switching is poor with arguably the best evidence for switching from a reuptake inhibitor to an MAOI. Three doubleblind studies in patients not responding to the first drug used a cross-over design (Thase et al., 1992; McGrath et al., 1993) or a random allocation to tranylcypromine or nomifensine (Nolen et al., 1988) and found that 50-75% of patients responded to the MAOI compared to 10-40% who responded to imipramine or
I. M. ANDERSON ET AL.: EVIDENCE-BASED GUIDELINES 11
Recommendations: Acute management Review patients every 1-2 weeks following commencement of antidepressant treatment (C). Telephone consultation and the use of suitably trained non-medical staff may appropriately take the place of some medical consultations (D).
At each review, response, compliance with drug treatment, sideeffects and suicidal risk should be assessed (C).
Educate patients about the nature of depressive disorders and the side-effects and benefits of medication (A).
Limit the total amount of antidepressant drug available to the patient to reduce risk if taken in overdose (D).
When prescribing an older TCA, or a drug requiring dose titration, increase the dose every 3-7 days to allow adjustment to side-effects (C).
Aim for a target dose for which there is established efficacy (usually 125 mg or above for most older TCAs but lower in the elderly) (C).
If a patient has responded to a lower than target dose of an antidepressant, the dose should still be increased to one of established efficacy, if possible, to reduce the likelihood of relapse in continuation treatment (D). Where this is not possible, continue the drug at the same dose and monitor the patient for relapse (D).
Dysthymia: treat using the same principles as for major depression (D). 
NRI, noradrenaline reuptake inhibitor; SRI, serotonin reuptake inhibitor; 5-HT 2 , 5-HT 2 antagonist; 5-HT 3 , 5-HT 3 antagonist; α 1 /α 2 , α 1 antagonist/α 2 antagonist; RIMA, reversible inhibitor of monoamine oxidase-A; ++, relatively common or strong; +, may occur or moderately strong; -absent or rare/weak; ?, unknown/insufficient information.
a These refer to symptoms commonly caused by muscarinic receptor blockade including dry mouth, sweating, blurred vision, constipation and urinary retention; however, the occurrence of one or more of these symptoms may be caused by other mechanisms and does not necessarily imply that the drug binds to muscarinic receptors. The side-effect profiles given are not comprehensive and are for an approximate comparison only. Details of drugs used and potential cautions and interactions should be looked up in a reference book such as the British National Formulary (1999). Sources: Lancaster and Gonzalez, 1989; Fitton et al., 1992; Depression Guideline Panel, 1993b; Feighner, 1994; Henry et al., 1995; Sitsen and Zivkov, 1995; Swinkels and de Jonghe, 1995; Baldwin et al., 1997; Davis et al., 1997; Pharmacia and Upjohn Limited, 1997. nomifensine. However, the study numbers were small with particular types of patients. For example, the largest involved mood reactive (atypical) patients, a group in whom TCAs may be generally less effective than MAOIs . With regard to other antidepressants, only a 23-27% response rate was seen in two separate double-blind cross-over studies involving non-responders originally randomized to fluvoxamine or oxaprotiline (a noradrenaline reuptake inhibitor) (Emrich et al., 1987; Nolen et al., 1988) . Otherwise, there are no satisfactory controlled trials; open studies find that approximately 20-60% of patients respond to switching antidepressants (Depression Guideline Panel, 1993b) or to switching between SSRIs (Thase et al., 1997) .
There is a lack of data on safe regimes for switching antidepressants. Clinical recommendations are available in the British National Formulary (1999) and the Maudsley Prescribing Guidelines (Taylor et al., 1999) .
Although total patients numbers were low, a meta-analysis of four RCTs demonstrated that augmentation of antidepressants with lithium carbonate can benefit non-responsive patients with major depression, with approximately 40% of patients responding to lithium compared and less than 10% to placebo (Austin et al., 1991) . A meta-analysis of augmentation with tri-iodothyronine, also involving a small total number of patients in only four RCTs found benefit with regard to improvement in HDRS score with a moderate effect size of 0.6 but a non-significant improvement in response rate of only 8% (NNT = 13) (Aronson et al., 1996) .
The better evidence for the efficacy of lithium augmentation compared with that of switching antidepressant drugs needs to be weighed against the risks associated with lithium treatment and the need to monitor serum lithium concentration.
There is some evidence that adjunctive cognitive therapy can reduce residual symptoms in successfully treated patients (Fava et al., 1994a) . There is also suggestive, but not conclusive, evidence that adjunctive cognitive or interpersonal psychotherapy may improve outcome in treatment resistant patients in psychiatric settings (Thase, 1997; Guthrie et al., 1999) .
ECT is reported to be effective in approximately 50% of treatment resistant patients in open studies, although the relapse rate in the 6-12 months following treatment is greater than 50% (Nobler and Sackeim, 1994) .
Continuation, maintenance and stopping treatment
A useful model of the course of major depression and its treatment proposes a continuum between depressive symptoms and major depression (Frank et al., 1991; Kupfer, 1991) . Initial acute treatment of major depression results in a significant lessening of depressive symptoms (response) progressing to absence of depressive symptoms (remission) which is return to the patient's premorbid state. Stable remission for 4-6 months is thought of as recovery. A worsening of symptoms or return of a major depression is considered a relapse before recovery has been achieved and recurrence if it occurs later. This model assumes that a single depressive episode has a discrete duration, but as this cannot be directly measured, and is likely to vary between individuals, the distinction between remission versus recovery and relapse versus recurrence is not always possible. Treatment until remission is described as acute, from remission to recovery as continuation and following recovery as maintenance.
How long to treat following response (continuation treatment)
Over one-third of patients with major depression relapse in the first year following initial remission with most relapses occurring in the first 4 months in adult patients (Ib) . In elderly patients, the risk of relapse may occur more steadily over 12 months (Ib) Rates of relapse following remission have been estimated as 20-24% by 2 months, 28-44% by 4 months, 27-50% by 6 months and 37-54% by 12 months from follow-up studies (Belsher and Costello, 1988) suggesting a high early risk that flattens off after approximately 4-6 months. Similar figures are described in general practice patients (Lin et al., 1998) with 37% relapsing in 1 year. In the elderly, the risk of relapse on placebo treatment may be spread more evenly over the 12 months after remission (Old Age Depression Interest Group, 1993) .
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Recommendations: Failure to respond Continue treatment for major depression for at least 4 weeks before considering switching antidepressant due to lack of efficacy (A); extend to 6 weeks in the elderly (D).
Non-response at 4 weeks: q check adequacy of treatment including dose and noncompliance: increase dose to recommended therapeutic dose if only a low or marginal dose has been achieved (D). q review diagnosis including possibility of additional physical or psychiatric diagnoses which should be treated in addition (D). q consider social factors and address if present (D).
Partial response after 4 weeks adequate treatment in adults: continue treatment with the same antidepressant for another 2 weeks (A).
No response after 4 weeks, or partial response after 6 weeks adequate treatment in adults; recommended options are to: q increase the dose (C). q switch treatment to another antidepressant class (C). q consider a switching to an MAOI in patients with 'atypical' major depression (C).
Elderly patients: consider continuing treatment for up to 9 weeks before changing (D).
Switching antidepressants: follow recommended precautions to avoid adverse drug interactions (D).
Failure to respond to a second antidepressant; principal treatment options are to: q add an augmenting agent (A). q add psychotherapy (B). q treat with ECT (C).
Augmentation therapy, the prescription of MAOIs and ECT should be undertaken by, or in consultation with, specialist psychiatric services (D).
Dysthymia: treat using the same principles as for major depression (D).
Continuation antidepressant treatment for 6 months halves the relapse rate (Ia)
A meta-analysis of controlled studies in which patients with major depression were treated for 2-6 months beyond the point of remission found a relative risk of relapse on antidepressants compared with placebo of approximately 0.5 (Loonen et al., 1991) . Fifty percent of patients receiving placebo relapse compared with 20-25% on antidepressants with most relapses occurring in the first 3-4 months (Prien and Kupfer, 1986; Belsher and Costello, 1988; Reimherr et al., 1998) . A naturalistic study supports the protective effect of antidepressants for 8 months after response (Dawson et al., 1998) . For patients with fewer than five previous episodes, the relapse rate after 8 months was 1% per week whether or not antidepressants were continued.
Antidepressant treatment continued beyond 6 months benefits patients with recurrent major depression (Ib) and probably elderly patients (Ib)
Continuing benefit of treatment for longer than 6 months after remission has not been demonstrated for non-selected groups of depressed patients, which include those experiencing a first episode , but has been shown for those with a history of recurrent depressive episodes. There is suggestive evidence that elderly patients may continue to benefit up to 12 months with 56% relapsing by 1 year on placebo compared with 29% on dothiepin in one study (Old Age Depression Interest Group, 1993) . The factors most consistently associated with relapse are higher levels of residual depressive symptoms, longer duration of the disorder or a chronic pre-existing depressive disorder, recurrent depressive disorder, greater severity of index illness and personality and social factors (Thase and Sullivan, 1995) .
Continuation of the effective acute treatment dose is associated with lower relapse rate than reduction to a lower dose (IIb)
In patients treated with relatively low doses of TCAs, those who relapsed had lower plasma tricyclic concentrations than those who did not in one study (Faravelli et al., 1986) . There is a lack of controlled evidence about effective dose in the continuation phase but a naturalistic study showed a benefit for continuing the acute treatment dose compared with reduction to a lower level (Dawson et al., 1998) . This concurs with evidence from maintenance studies.
Relapse is partly due to loss of placebo effect or reversal of spontaneous improvement (Ib)
Relapse during the continuation phase was three times higher in patients responding to, and continued on, placebo compared with antidepressants (Quitkin et al., 1993) . This relapse rate on placebo is similar to that seen when responders to an antidepressant are switched to placebo (Montgomery et al., 1993b) . However, the pattern of response also seems to be important. Patients treated with fluoxetine who showed an early abrupt, inconsistent response, which has been attributed to placebo effects (Quitkin et al., 1991a,b) , did no better on continued fluoxetine treatment compared with continuation placebo in a recent study (Stewart et al., 1998) . In contrast, those showing a progressive sustained response pattern (associated with drug or spontaneous response) did show a benefit from continuing fluoxetine compared with placebo and fared better than patients with early abrupt, inconsistent response (Stewart et al., 1998) .
Data are lacking on treatment of relapse during continuation treatment with antidepressants. Evidence from an open trial in dysthymia suggests that the acute benefits of antidepressants are sustained up to 6 months with continuing treatment .
Preventing recurrence (maintenance treatment)
Maintenance antidepressant drug treatment reduces the recurrence rate in patients who have had three or more episodes of major depression in the last 5 years or more than five episodes altogether (Ib-IIb) Controlled studies involving patients who had experienced recurrent depressive episodes (typically three in the last 5 years) have demonstrated that continuation of an antidepressant after recovery prevents recurrence over the next 1-5 years (Montgomery, 1994) . Frank et al. (1990) showed that after 3 years maintenance treatment, 80% of patients on placebo but only 20% on imipramine had a recurrence. Interpersonal psychotherapy did not enhance the effect of imipramine and had a weaker effect on its own. A 5 year naturalistic study showed continuing benefit from antidepressant treatment beyond 28 weeks for patients who had five or more prior episodes but not for those with fewer episodes (Dawson et al., 1998) .
In elderly patients, the benefits of preventing recurrence of major depression in the remaining years of life needs to be balanced against the risks of continuing treatment. In an open study of elderly patients with a first episode major depression, 61% suffered a recurrence of depression over the subsequent 2 years following discontinuation of 2 years maintenance treatment (Flint and Rifat, 1999) but we are not aware of any controlled data.
The recurrence rate is lower when treatment is maintained with the effective acute treatment dose compared with reduction to half the dose (Ib)
Two controlled studies have shown a higher rate of recurrence when maintenance treatment was continued at half the acute 14 JOURNAL OF PSYCHOPHARMACOLOGY 14(1)
Recommendations: Continuation treatment
Continue antidepressant drug treatment for a minimum of 6 months after remission of major depression (A), 12 months in the elderly (B).
Continue the same dose of antidepressant as used during the acute phase (B).
Patients with recurrent major depression should go on to receive maintenance antidepressant drug treatment (A).
Patients with residual depressive symptoms and other factors increasing risk of relapse of major depression: continue treatment for longer with the duration taking into account the persistence of these factors (D).
Relapse during the continuation phase: treat using the same principles applied to non-response to treatment (D).
Dysthymia: treat using the same principles as for major depression (D). treatment dose compared with the full dose over 2-3 years (Frank et al., 1993; Franchini et al., 1998) . A third study in elderly patients with recurrent major depression found that patients randomized to receive nortriptyline with their plasma concentration maintained at effective acute treatment levels, compared to patients with half this level, had significantly fewer residual depressive symptoms and non-significantly fewer episodes of recurrence (Reynolds et al., 1999) .
Lithium is an alternative to antidepressants for maintenance treatment (Ia)
A meta-analysis of eight small studies comparing lithium to placebo and antidepressants found lithium to be more effective than placebo and no different from antidepressants in preventing depressive relapse/recurrence in unipolar depressed patients over 5 months to 3 years (Souza and Goodwin, 1991) .
Evidence is lacking on the best way to treat recurrence while on maintenance treatment and on the efficacy of maintenance treatment for dysthymia.
Stopping antidepressant drug treatment
The main reasons for choosing to stop antidepressants are adverse reactions, including switching from depression into hypomania/ mania (Peet, 1994) , and recovery from depression as outlined above. In patients without a history of mania, the rate of switching is low (less than 1%) (Peet, 1994 (Dilsaver et al., 1987; Lejoyeux and Adès, 1997; Haddad, 1998; Rosenbaum et al., 1998) . Symptoms are mild for most patients and usually resolve within a few days to 3 weeks, but may be particularly severe with MAOIs from case reports (Lejoyeux and Adès, 1997) . Discontinuation reactions appear less likely in shorter courses of treatment and if the drug dose is gradually tapered but controlled evidence is lacking. Evidence from a controlled study with SSRIs , and case reports, indicate that reinstatement of the original drug relieves the discontinuation symptoms. Comparative data are only available for SSRIs where paroxetine appears most likely, and fluoxetine least likely to cause discontinuation reactions; the latter may be related to the long halflife of fluoxetine. The reported incidence has varied widely (Lejoyeux and Adès, 1997) with no evidence on relationship to dose. Antidepressants in general appear to have little potential for abuse (Pagliaro and Pagliaro, 1995) , although case reports suggest that addiction can rarely occur with the dopaminergic antidepressants tranylcypromine and amineptine (Haddad, 1999) . There is no evidence that discontinuation reactions are part of a general syndrome of addiction to antidepressants.
Discontinuation symptoms differ in pattern from those of depressive relapse (Ib)
Common symptoms are balance and sensory disturbance, gastrointestinal symptoms (as well as insomnia and mood abnormalities) and a pattern different from re-emergence of the original depressive disorder (Haddad, 1998; Rosenbaum et al., 1998) .
There is a lack of evidence about tapering the dose when switching between antidepressants. There are no controlled data on
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Recommendations: Stopping treatment Consider the possibility of a discontinuation reaction in any patient who stops antidepressant drug treatment (A).
Warn patients that a discontinuation reaction may occur if treatment is abruptly stopped after a few weeks treatment (B).
Taper the dose (or frequency) over a minimum of 4 weeks if possible when antidepressant drug treatment is to be stopped (D). Rapid discontinuation may be required for severe adverse reactions or if the patient switches into a hypomanic state (D).
Taper the dose over 6 months in patients who have been on longer-term maintenance treatment (D).
If a discontinuation reaction does occur: q explanation and reassurance are often all that is required. q if this is not sufficient, and for more severe reactions, the antidepressant should be restarted and tapered more slowly (C).
Switching antidepressants: judge the rate of taper against clinical priorities and take the need for any washout period into account (D).
Recommendations: Maintenance treatment
Maintenance treatment with antidepressants is indicated for patients with: q three or more episodes of major depression in the last 5 years (A). q more than five episodes altogether (B). q fewer recurrent depressive episodes with persistent risk factors for relapse/recurrence (D).
Maintain the same dose of antidepressant as used to treat the acute episode (B).
Treat for at least 5 years (A) and possibly indefinitely (D).
Lithium is an effective second-line alternative to antidepressants for maintenance treatment (B).
Recurrence of depression: treat using the same principles applied to non-response to treatment (D).
discontinuation of maintenance antidepressant treatment where there is also the issue of illness recurrence. The optimum rate to taper drug dose is unknown with opinions varying from a few weeks to a year (Greden, 1993) . 
